AGIO
HealthcareAgios Pharmaceuticals, Inc.
$27.45
+$0.27 (+0.99%)
Jan 5, 2026
Price History (1Y)
Analysis
Agios Pharmaceuticals, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $1.60 billion and approximately 486 employees. The company's scale is substantial, with revenue exceeding $44 million on a trailing twelve-month basis. Financially, Agios Pharmaceuticals has demonstrated significant losses, with net income and EBITDA both negative at -$401 million and -$470 million, respectively. Profitability metrics are severely impacted, with gross margin, operating margin, and profit margin all approaching 0%. Returns on equity and assets are also negative, at -27.6% and -18.7%, respectively. The company's balance sheet is characterized by a substantial cash position of $953 million and relatively low debt levels of $45 million. Valuation metrics are challenging to interpret due to the presence of negative earnings figures, resulting in a forward P/E ratio of -4.26. Revenue growth has been robust at 43.7% year-over-year, although the lack of dividend payments and payout ratio indicates that no dividends have been distributed.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $1.60B
- P/E Ratio
- N/A
- 52-Week High
- $46.00
- 52-Week Low
- $22.24
- Avg Volume
- 1.52M
- Beta
- 0.89
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 486